Alembic Pharma gets USFDA EIR for API III facility at Karakhadi
Vadodara: Alembic Pharmaceuticals Limited has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its API-III Facility at Karakhadi.
The inspection was held from 17 th March, 2025 to 21st March, 2025.
Read also: Alembic Pharma Karakhadi facility successfully completes USFDA inspection
Headquartered in India, Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also: USFDA clears Alembic Pharma cardio drug Rivaroxaban, launch expected in next year
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.